Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study)

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84).

The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, women only.

The researchers measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) or alendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

PubMed files the paper under topics including Adiponectin, Adiposity, Alendronate, Bone Density, Bone Density Conservation Agents, Osteocalcin and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized and double-blind study of Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.